Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin (IL)-17A, is approved for the treatment of moderate-to-severe psoriasis.
An overview has analyzed the efficacy outcomes from three phase III psoriasis studies.
Data were integrated from the 12-week induction period of three studies in which patients received Ixekizumab 80 mg every 2 weeks ( IXE Q2W; n = 1169 ) or every 4 weeks ( IXE Q4W; n = 1165 ) after an initial 160-mg dose for both; Etanercept ( 50 mg biweekly; n = 740; two studies ) or placebo ( n = 792 ).
The coprimary end points were the percentages of patients with response of static Physician's Global Assessment ( sPGA; score 0 or 1 ) and greater than or equal to 75% improvement in baseline Psoriasis Area and Severity Index ( PASI 75 ) at week 12.
Treatment comparisons with placebo included data from three studies, whereas Etanercept comparisons were based on two studies.
Ixekizumab treatment was superior to placebo ( P less than 0·001 ) and Etanercept ( P less than 0·001 ) on sPGA ( 0, 1 ) and PASI 75, with significant differences in PASI improvement at week 1.
With IXE Q2W, at week 12, the frequencies of patients achieving PASI 75, 90 and 100 were nearly 90%, 70% and 40%, respectively.
Ixekizumab-treated patients showed significantly greater improvement versus placebo and Etanercept in percentage body surface area involvement and fingernail psoriasis.
IXE Q2W was superior to IXE Q4W on all treatment outcomes.
In conclusion, Ixekizumab therapy at both dosing regimens demonstrated rapid onset and superior efficacy to placebo and Etanercept, with IXE Q2W providing better outcomes than IXE Q4W during the first 12 weeks of treatment. ( Xagena )
Papp KA et al, Br J Dermatol 2018;178: 674-681